Abstract:Objectives Docosahexaenoic acid (DHA) is routinely recommended to adequate fetal development during gestation. Since it is a substance with intense anti‐inflammatory action, its effects upon the fetal heart and circulation are unknown and safety of its administration during gestation is not yet established. This randomized clinical trial was designed to investigate if maternal supplementation of DHA is followed by alterations of maternal prostaglandin levels and fetal ductus arteriosus flow dynamics, at the final trimester of pregnancy. Methods A double blind, placebo‐controlled, randomized clinical trial by parallel groups was designed. The study was developed in the period of 2018 to 2021. Pregnant women above 18 years of age, at 27 or 28 weeks without cardiac alterations at fetal echocardiography were enlisted to the trial, with exclusion of those taking substances with known prostaglandin inhibition effect, such as nonsteroidal anti‐inflammatory drugs and polyphenol‐rich foods. The intervention group received oral supplementation of omega‐3 with 450 mg/day of DHA, and the placebo group received capsules of soy lecithin. Both groups were supplemented for eight weeks. The following data were obtained at the beginning and at the end of the follow‐up: anthropometric, assessment of polyphenol and omega‐3 consumption, fetal morphological ultrasound, fetal Doppler echocardiographic examination and blood draw to assess prostaglandin levels. Participants were considered eligible, without cardiac or extracardiac abnormalities, when the diagnosis of ductal constriction was excluded by two observers. Intergroup and intragroup data were evaluated. Results The study ended up with 24 participants in each group. After 8 weeks, Doppler echocardiographic parameters of ductal flow and serum prostaglandin levels in both groups did not show significant intergroup differences. The expected intragroup differences as a result in increase in gestational ages were present. Conclusions Even though complete safety of DHA has not been tested, this randomized clinical trial shows that third trimester maternal supplementation of DHA, at the doses and period used, does not result in inhibition of PGE2 and does not cause ductus arteriosus constriction, providing the basis for post‐market surveillance studies with larger numbers, to allow the best clinical reassurance. This article is protected by copyright. All rights reserved.

Maternal supplementation of DHA does not cause fetal ductus arteriosus constriction: randomized controlled trial

DHA, nutrient intake, and maternal characteristics as predictors of pregnancy outcomes in a randomised clinical trial of DHA supplementation

Docosahexaenoic Acid Supplementation in Gestational Diabetes Mellitus and Neonatal Metabolic Health Biomarkers

Effect of n-3 long-chain polyunsaturated fatty acids supplementation in healthy mothers on DHA and EPA profiles in maternal and umbilical blood: a randomized controlled trial

Maternal Docosahexaenoic Acid Supplementation Alters Maternal and Fetal Docosahexaenoic Acid Status and Placenta Phospholipids in Pregnancies Complicated by High Body Mass Index

Maternal high-dose docosahexaenoic acid supplementation and neurodevelopment at 5 Years of preterm children

Prenatal effects of maternal consumption of polyphenol-rich foods in late pregnancy upon fetal ductus arteriosus

Effect of DHA supplements during pregnancy on the concentration of PUFA in breast milk of Chinese lactating mothers.

Self-Reported DHA Supplementation during Pregnancy and Its Association with Obesity or Gestational Diabetes in Relation to DHA Concentration in Cord and Maternal Plasma: Results from NELA, a Prospective Mother-Offspring Cohort

The Influence of Prenatal DHA Supplementation on Individual Domains of Behavioral Functioning in School-Aged Children: Follow-Up of a Randomized Controlled Trial

Maternal FADS2 single nucleotide polymorphism modified the impact of prenatal docosahexaenoic acid (DHA) supplementation on child neurodevelopment at 5 years: Follow-up of a randomized clinical trial

Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)-Should They Be Mandatory Supplements in Pregnancy?

DHA supplementation and pregnancy complications

Could early life DHA supplementation benefit neurodevelopment? A systematic review and meta-analysis

Multiple Micronutrients and Docosahexaenoic Acid Supplementation during Pregnancy: A Randomized Controlled Study

Prenatal Supplementation of Docosahexaenoic Acid for the Management of Preterm Births: Clinical Information for Practice

Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth?

Supplementation of Female Rats with α-Linolenic Acid or Docosahexaenoic Acid Leads to the Same Omega-6/Omega-3 LC-PUFA Accretion in Mother Tissues and in Fetal and Newborn Brains

Maternal Omega-3 Nutrition, Placental Transfer and Fetal Brain Development in Gestational Diabetes and Preeclampsia

Impact of perinatal maternal docosahexaenoic acid-containing phospholipid synthesis on offspring growth and neurological symptoms

Docosahexaenoic Acid Supplementation for Neonatal Hyperbilirubinemia: A Double-Blind, Randomized Clinical Trial